Therapeutic Opportunities for Pharma - Preventive cardiology solutions for the women at risk postmenopause
Once reconstituted, that stability window shrinks to 28 days under refrigeration
doi: 10.1016/j.diabres.2017.01.012 5 SzadkowskaAMadejAZiolkowskaKSzymanskaMJeziornyKMianowskaBet al
This lack of mention is significant, as pharmaceutical companies are required to report all observed and statistically relevant adverse events during clinical trials
However, these findings are preliminary and hypothesis-generating rather than evidence of protective effects in humans
On the clinical research side: CDER reviewed clinical data submissions for more than 150 marketing applications, investigated over 900 complaints related to bioresearch violations, and issued 21 official action indicated (OAI) / Form 483 findings, including instances where companies failed to submit required investigational new drug (IND) applications